西班牙耐药菌感染相关住院费用的全国队列研究
该研究基于西班牙全国住院登记数据,纳入2017至2022年成人细菌感染住院病例,采用广义线性模型分析抗菌药物耐药(AMR)与住院费用的关联。
要点
- AMR与住院费用增加15%独立相关(费用比1.15,95%CI 1.15-1.16)。
- 每例AMR住院增量费用为925欧元(95%CI 887-962)。
- 归因经济负担以腹腔感染、急性肾盂肾炎、肺炎和下尿路感染最高。
核心结论
- 在西班牙全国队列中,AMR与住院费用增加独立相关,对国家医疗支出有显著贡献。
主要发现
- 共纳入2,817,406例细菌感染住院,其中175,188例(6.22%)涉及AMR。
- 调整人口学和临床特征后,AMR与住院费用增加15%相关(费用比1.15,95%CI 1.15-1.16;p<0.0001),每例增量费用925欧元(95%CI 887-962)。
- 归因经济负担在腹腔感染、急性肾盂肾炎、肺炎和下尿路感染中最高。
临床怎么用
- 应关注AMR相关住院的额外经济负担,尤其针对腹腔感染、急性肾盂肾炎、肺炎和下尿路感染等高负担感染类型优化抗菌药物管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial resistance (AMR) is a major global health threat with substantial clinical and economic consequences. However, robust national estimates of the economic burden of AMR-related hospitalizations to AMR remain limited. We aimed to quantify the hospitalization costs attributable to AMR in Spain and to assess their variation across infection types. METHODS: We conducted a nationwide, retrospective cohort study using the Spanish Specialized Care Activity registry (RAE-CMBD). We included all adult hospitalizations with a diagnosis of bacterial infection between Jan 1, 2017, and Dec 31, 2022. AMR was defined using ICD-10-CM resistance diagnosis codes.Hospitalization costs were estimated using nationally standardized APR-DRG cost weights. Generalized linear models were used to estimate the incremental cost associated with AMR after adjustment for demographic and clinical characteristics. RESULTS: Among 2,817,406 hospitalizations with bacterial infection, 175,188 (6.22%) involved AMR. In adjusted analyses, AMR was associated with a 15% increase in hospitalization costs (cost ratio 1.15, 95% CI 1.15-1.16; p<0.0001), corresponding to an incremental cost of EUR 925 (95% CI 887-962) per hospitalization.The cost of hospitalizations with bacterial AMR infections was EUR 215 million annually (95% CI 213.33-216.67). After adjustment for patient and clinical characteristics, the attributable economic burden of AMR was EUR 27.10 million annually. This economic impact of AMR varied substantially across infection types, with the greatest attributable economic burden intra-abdominal infections, acute pyelonephritis, pneumonia, and lower urinary tract infections. CONCLUSIONS: In this nationwide cohort, AMR was independently associated with an increase in hospitalization costs in Spain, contributing meaningfully to national healthcare expenditure.
引用
- Oterino-Moreira I, Pérez-Encinas M, Lorenzo-Martinez S, et al. Hospitalization Costs Attributable to Antimicrobial Resistance in Spain: A Nationwide Cohort Study. J Infect Dis. 2026. PMID: 42566655. doi:10.1093/infdis/jiag405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。